Dr Reddy's Laboratories lost 2.16% to Rs 2,036 at 14:08 IST on BSE after consolidated net profit surged 66.58% to Rs 570.89 crore on 30.79% growth in total income to Rs 3503.04 crore in Q4 March 2013 over Q4 March 2012.
The company announced Q4 results during trading hours today, 14 May 2013.
Meanwhile, the S&P BSE Sensex was up 60.70 points or 0.31% at 19,752.37.
On BSE, 1.05 lakh shares were traded in the counter as against average daily volume of 15,375 shares in the past one quarter.
The stock hit a high of Rs 2,119.90 and a low of Rs 2,025 so far during the day. The stock had hit a record high of Rs 2,150.90 on Monday, 13 May 2013. The stock had hit a 52-week low of Rs 1,528 on 19 June 2012.
The stock outperformed the market over the past one month till 13 May 2013, surging 9.43% compared with the Sensex's 7.94% rally. The scrip had also outperformed the market in past one quarter, jumping 9.2% as against Sensex's 0.43% rise.
The large-cap company has equity capital of Rs 84.91 crore. Face value per share is Rs 5.
Dr Reddy's Laboratories' consolidated net profit rose 17.62% to Rs 1677.62 crore on 21.78% growth in total income to Rs 11874.46 crore in the year ended 31 March 2013 (FY 2013) over the year ended 31 March 2012 (FY 2012).
Dr Reddys Laboratories' board of directors at a meeting held today, 14 May 2013, recommended final dividend of Rs 15 per share for FY 2013.
Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses -- pharmaceutical services and active ingredients, global generics and proprietary products -- Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
